Compounds > amsacrine

amsacrine and icrf 193

amsacrine has been researched along with icrf 193 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andoh, T; Hamatake, M; Ishida, R; Nitiss, JL; Wang, JC; Wasserman, RA1
Aratani, Y; Fujimaki, K; Fujisawa, S; Koyama, H; Motomura, S; Okubo, T1
Jensen, LH; Jensen, PB; Møller, M; Nitiss, JL; Sehested, M; Wessel, I1
Andersen, AH; Knudsen, BR; Oestergaard, VH1
Hung, VK; Mak, CK; Wong, JT1

Other Studies

5 other study(ies) available for amsacrine and icrf 193

ArticleYear
DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Cancer research, 1995, Jun-01, Volume: 55, Issue:11

    Topics: Amsacrine; Antineoplastic Agents; Diketopiperazines; DNA Topoisomerases, Type II; Drug Hypersensitivity; Drug Resistance; Piperazines; Razoxane; Saccharomyces cerevisiae; Topoisomerase II Inhibitors

1995
DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes.
    Somatic cell and molecular genetics, 1996, Volume: 22, Issue:4

    Topics: Amsacrine; Cell Line; Chromosomes, Human; Diketopiperazines; DNA Damage; Enzyme Inhibitors; Etoposide; Genetic Vectors; HeLa Cells; Humans; Kinetics; Piperazines; Plasmids; Recombination, Genetic; Topoisomerase II Inhibitors; Transfection

1996
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
    FEBS letters, 2000, Sep-01, Volume: 480, Issue:2-3

    Topics: Adenosine Triphosphate; Amsacrine; Antigens, Neoplasm; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Piperazines; Razoxane; Topoisomerase II Inhibitors

2000
Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193.
    The Journal of biological chemistry, 2004, Jul-02, Volume: 279, Issue:27

    Topics: Amsacrine; Antineoplastic Agents; Apoptosis; Catalysis; Diketopiperazines; DNA; DNA Damage; DNA, Complementary; Enzyme Inhibitors; Gene Deletion; Humans; Mutation; Piperazines; Plasmids; Protein Structure, Tertiary; Saccharomyces cerevisiae; Time Factors; Topoisomerase II Inhibitors

2004
Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.
    Chromosoma, 2005, Volume: 114, Issue:6

    Topics: Amsacrine; Animals; Cell Cycle; Chromosomes; Diketopiperazines; Dinoflagellida; DNA Damage; DNA Fragmentation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Ellipticines; Enzyme Inhibitors; Piperazines; Topoisomerase II Inhibitors

2005